Short answer
DaVita (DVA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). DaVita announced financial results for the quarter ended September 30, 2026.
DaVita 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- DaVita announced financial results for the quarter ended September 30, 2026
- Full revenue, earnings and operating details are in Exhibit 99.1, the attached earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $3.578B, operating income $499M, adjusted EPS $3.82, with adjusted operating margin 15.7%
- Adjusted 2026 operating-income guidance raised to $2.175B-$2.250B from prior low of $2.150B
- China impairment charge $62M reduced attributable net income by $27M, depressing GAAP EPS versus adjusted EPS
- Patient care costs rose to $280.22 per treatment while revenue per treatment fell to $415.25, pressuring dialysis margins
- Share repurchases accelerated: 0.6M shares for $111M in Q3, plus 0.5M shares for $87M through October 27
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DaVita 8-K filings
Get the next DVA 8-K as it lands
Follow DVA for push alerts, or ask the research agent what this filing means.